Reference Committee for the Health Technology Assessment Policy and Methods Review

Page last updated: 27 October 2022

On 6 September 2021, the Commonwealth entered into a new Strategic Agreement in relation to reimbursement, health technology assessment and other matters with Medicines Australia acting on behalf of the innovator medicines industry (Strategic Agreement).

Under clause 5.3 of the Strategic Agreement, it was agreed that the Commonwealth would support and resource a Health Technology Assessment (HTA) Policy and Methods Review (Review).

On 27 October 2022, the Minister for Health and Aged Care, the Hon Mark Butler MP, announced the following members to serve on the Reference Committee for the HTA Review.

• Independent Chair: Adjunct Professor Debora Picone AO
• Patient Representatives: Ms Ann Single and Dr Dawn Casey PSM
• Chair of the Pharmaceutical Benefits Advisory Committee (PBAC): Professor Andrew Wilson
• Clinical/Scientific Representative: Professor Andrew Roberts AM
• Industry Representative: Mr John Young
• Government Nominee: Ms Adriana Platona PSM

The functions of the Reference Committee include:

• Agreeing the terms of reference for the HTA Review
• Agreeing the expert in HTA to undertake an analysis of current methods used by PBAC, contemporary research and relevant methodologies and purchasing practices used by comparable jurisdictions
• Overseeing public consultations and considering submissions to the HTA Review
• Overseeing the analysis undertaken by the expert in HTA
• Preparing and agreeing the final review report and recommendations

For further information about the HTA Review, please visit the HTA Policy and Methods Review page.